MLKL and Alzheimer disease: These results strongly support the likelihood that the MLKL stop-gain variant contributes to AD pathogenesis, but in contrast to the findings of Wang et al., three of the four carriers identified in this study were APOE ε4-positive patients, suggesting that this variant contributes to AD pathogenesis irrespective of APOE ε4 allele status in the Japanese population.